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 ABSTRACT 
The Amyloid-β (Aβ) peptide is the main component of the the amyloid plaques in 
Alzheimer’s Disease (AD) and has been implicated to be the cause of the disease. 
During the last decade it has become increasingly evident that soluble, oligomeric 
forms of Aβ are more toxic to neurons than the plaques and might play an important 
role in the disease pathogenesis. The aim of this thesis was to investigate the time 
course of different Aβ isoforms and species and how these forms affects the neuro-
pathological changes seen in AD and how different cholinergic drugs can modulate 
Aβ and it’s processing. 
A translational approach ranging from transfected human neuroblas-
toma SH-SY5Y/APPswe cells, APPswe and hAChE-Tg//APPswe transgenic mouse 
models of AD to postmortem AD brain tissue were used to study how changes of 
different levels of Aβ influence the brain and related processes. 
APPswe transgenic mice showed already at 7-days of age, high le-
vels of soluble form of Aβ, as a sign for that Aβ starts to aggregate from birth. Be-
tween 7 to 90-days of age, the major Aβ isoforms in brain were shorter forms than 
Aβ1-40. The levels of Aβ1-40  were high and remained fairly constant up to 15- 
months of age while Aβ1-42 showed an age-dependent consistent increase from 7- 
days up to 15-months of age. High levels of Aβ oligomers but low levels of syn-
aphtophysin were observed in 90-days-old APPswe mice probably due to the tox-
icity of the oligomers. Low levels of α7 neuronal nicotinic acetylcholine receptors 
(nAChRs) compared to non-transgenic mice were measured in 7-days-old APPswe 
mice; while an increased number N-methyl-D-aspartate (NMDA) receptors bind-
ing sites were found at 21-days of age probably reflecting compensatory mechan-
isms in response to a high Aβ burden. Epigenetic studies showed increased levels 
of acetylated (AcH3), and di-methylated (2MeH3) histone H3 at 4-months-old 
APPswe mice. When a γ-secretase inhibitor reduced Aβ, there was a reduction in 
AcH3 in SH-SY5Y/ APPswe cells. nAChR agonists showed to influence the Aβ 
levels in hAChE-Tg//APPswe transgenic mice and in SH-SY5Y/ APPswe cells. 
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INTRODUCTION 
ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is the most common neurodegenerative disease 
among the elderly population, causing insidious and progressive damage to the brain, 
leading to memory loss. According to the recent WHO report in April 2012, the 
present number of patients with dementia is 35.6 million and is expected to increase 
to 106 million in 2050. It is estimated that the global prevalence of dementia will be 1 
in 85 persons by 20501. This means that every year around 7.7 million people are af-
fected with dementia, estimating one new case in every four seconds2. AD is the most 
common form of dementia disorder representing 50-70% of cases over 65 years of 
age. The incidence rate of AD increases  exponentially with increasing age. Every 5-6 
years of time, the number of AD patients is duplicated . The prevalence of AD is 1% 
at 60-65 years of age; thereafter, it increases to 24-33% at the age of 853. A recent 
study showed that AD affected 34 million people worldwide in 2009 and the esti-
mated cost was $422 billion, which had increased by 34% between 2005 and 20094.  
AD is characterized initially with subtle impairment in episodic memory, 
which also starts to involve other memory domains. Besides memory impairments, 
this disease also includes damages of other functions in the brain resulting in impair-
ments of personality and behavior, speaking as well as executive functions such as 
decision-making and planning which seriously interfere with daily life. AD affects 
not only the afflicted patients but also close relatives as well as the society. The cause 
of death is usually due to secondary conditions such as pneumonia or other infections 
and malnutrition. 
 
Risk factors and genetics  
The AD cases are categorized as:  sporadic AD (sAD) or late onset AD (irregular and 
amorphous occurrence of AD), and familial AD (FAD) or early onset AD (inherited as 
autosomal-dominant disorder). sAD is the most common since FAD represents less 
than 2% of all AD cases5. FAD generally has a relatively early onset (< 60 years of 
age), while sAD has a later onset 6.  
sAD is diverse and its causal factor(s) that triggers the disease process are not ful-
ly understood. However a combination of both biological and environmental risk fac-
tors may attribute to the cause7. Advancing age is the greatest risk for developing AD8. 
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In addition to family history9,10, stroke 11, low education levels12, female gender13, and 
diabetes14,15 are also risk factors. The inheritance of one or two ε4 alleles of apolipo-
protein E (ApoE) gene on chromosome 19q13, a protein involved in cholesterol meta-
bolism contributes to the risk of late onset AD16-18.  
There are three genes that have been identified in which mutations lead to the 
development of FAD: presenilin 1 (PS1) on chromosome 1419, presenilin 2 (PS2) on 
chromosome 120 and amyloid-β protein precursor (APP) on chromosome 2121. All these 
mutations alter the proteolytic processing of APP, resulting in increased production of 
either total Aβ or Aβ1–4222.  
More than 70% of FAD cases are due to the mutations in the PS1 gene. These 
mutations cause the most aggressive forms of AD, in some cases with onset younger 
than 30 years of age19,23. Mutations in the PS1 or PS2 genes cause a selective increase 
in Aβ1-42 levels24,25. It was suggested that PS mutations selectively elevate the levels 
of highly amyloidogenic Aβ1-42 peptides by shifting the cleavage site in APP26. 
A number of mutations in the APP gene have been identified causing different 
phenotypes of onset and progression of the disease processes: Dutch27, Flemish28, 
London 29, Arctic30, Australian31, Belgian32, German33 and Swedish mutation34. The 
Swedish APP mutation (KM670/671NL) occurs near the β-site adjacent to the Aβ 
domain, increasing the production of APP which in turn leads to elevation of the ab-
solute levels of both Aβ1-40 and Aβ1-4235. All these mutations in the APP gene are gen-
erally believed to cause Aβ accumulation by formation of protofibrils30,36,37. 
  
Clinical diagnosis 
AD is diagnosed according to the criteria of the Diagnostic and Statistical Manual of 
Mental Disorders, fourth edition (DSM-IV) 38, National Institute of Neurological and 
Communication Disorders and Stroke-Alzheimer’s disease and Related Disorders As-
sociations (NINCDS-ADRDA)39. For the assessment of memory problems, the pa-
tient undergoes investigations including disease history, neurological and psychiatric 
assessments, blood analysis, cognitive testing and brain imaging (CT or MRI). At 
more specialized memory clinics the investigations might also include cerebrospinal 
fluid (CSF) sampling for analysis of biomarkers and positron emission tomography 
(PET) or single photon emission tomography (SPECT) imaging. Recent progress in 
the development of new diagnostic biomarkers suggesting the incorporation of  bio-
markers such as CSF and PET into the standardized clinical diagnosis of AD which 
might in the near future change the diagnostic guidelines40-43.  
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Pathogenesis 
The pathogenesis of AD is highly complex. Scientists have identified several factors 
that appear to play a role in the development of AD, but no definitive causes or me-
chanisms have been singled out. In 1906, Dr. Alois Alzheimer presented the first case 
of AD, a 51-year-old woman named Auguste Deter. In her autopsied brain, he de-
scribed the extracellular accumulation of β amyloid (Aβ) and intracellular neurofibril-
lary tangles (NFTs) consisting of hyperphosphorylated tau under the microscope 44. 
These two features still serve as the major pathological hallmarks of AD. The AD brain 
shows atrophy along with shrinkage of gyri, widening of sulci, and enlargement of ven-
tricles. The cortical ribbon may be thinned, therefore, ventricular dilatation becomes 
obvious, especially in the temporal horn, due to atrophy of the amygdala and hippo-
campus45. The two pathological hallmarks of AD are found mainly in the brain paren-
chyma, especially in the cerebral cortex and hippocampus but also in the entorhinal cor-
tex,  neocortex 46; furthermore, they are accompanied by other structural changes like 
granulovascular degeneration, dendritic atrophy, and synapse loss, especially choliner-
gic neurons being vulnerable47. In addition, the presence of inflammatory markers such 
as reactive microglia, astrocytes, and pro-inflammatory cytokines around the Aβ pla-
ques reveal the existence of inflammation in AD brains48-50. 
 
Amyloid Precursor Protein (APP) processing 
Amyloid- β precursor protein (APP) is a transmembrane glycoprotein containing a 
47-residue cytoplasmic domain and one membrane-spanning domain51. The specific 
form of APP plays a key role in the modulation of neuronal plasticity, synapse stabi-
lization, and memory consolidation52. Within the APP structure there are 40 and 42 
amino acid sequences termed the Aβ region, which is located partly within the mem-
brane (amino acids 29-42), and partially in the extracellular space (amino acids 1-28).  
The exact biological function of APP and its homologues is still unknown. 
However, several in vitro and in vivo studies have provided strong evidence of the 
roles of APP on CNS such as: both in the developing and adult nervous system, in 
cell adhesion, neurite outgrowth, synaptogenesis, and modulation of synaptic plastici-
ty, neuronal survival, vesicular transport, neuronal migration, and insulin as well as 
glucose homeostasis. 
APP can be processed in two distinct reciprocal proteolytic pathways: a non-
amyloidogenic (or α-secretase) and an amyloidogenic (or β-secretase) pathway (Fig. 
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1). Although APP processing has been studied extensively, there is not yet a complete 
picture of the processing events and the enzymes involved 53. 
The non-amyloidogenic pathway is the major APP processing pathway in 
most cell types54. It is initiated by the cleavage at the α-secretase site by a member of 
the ADAM (adisintegrin and metalloprotease) family, of which ADAM10, ADAM9 
55,56, ADAM17 (TACE) 57 and ADAM19 have been identified as having α-secretase 
activity 58,59.  
 
 
 
Figure 1. Schematic overview of the general processing of amyloid precursor protein. In non-
amyloidogenic processing, APP is sequentially cleaved by α- and γ-secretase while in the amyloidogenic 
pathway APP is processed by β- and γ-secretase generating Aβ.  
 
The cleavage occurs within the Aβ region (between residue 16 and 17), thereby pre-
venting the formation of Aβ, generating a soluble extracellular fragment of APP 
(sAPPα). The sAPPα may have neuroprotective functions60 and a membrane-associated 
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C-terminal fragment (CTFα) of 83 residues which is further processed by γ-secretase 
complex, generating a short p3 peptide, unable to form aggregates, and the APP intra-
cellular domain (AICD). 
In the amyloidogenic pathway, APP is processed by aberrant cleavage at the 
β-secretase site by the β-site cleaving enzyme (BACE), producing a large soluble N-
terminal ectodomain fragment of APP (sAPPβ), and an Aβ-bearing membrane-
associated C-terminal fragment (CTFβ) of 99 residues that are further processed within 
the transmembrane domain by γ-secretase complex, and generate Aβ1-40 and Aβ1-42 
61,62. In addition, a soluble cytosolic fragment APP intracellular domain (AICD) is 
liberated. AICD can be translocated into the nucleus where it may function as a tran-
scription factor63. The β-secretase has been shown to be the novel transmembrane as-
partic protease, β-site APP-cleaving enzyme 1 (BACE1). BACE2, a protease homo-
logous to BACE1, was also identified 64. γ-secretase is a multiprotein 
complex consisting of presenilin-1 (PS1), nicastrin, Aph-1 (anterior pharynx-
defective-1), and Pen-2 (PS-enhancer-2); all four proteins are necessary for full pro-
teolytic activity65.  
Both α and β-secretase activity result in release of the large, extracellular 
sAPP domain. sAPPα has been reported to have neurotrophic properties in vitro 66,67. 
Thus, any condition that favor Aβ production from APP, may lead to loss of neuro-
protective sAPPα, along with the added neurotoxic effect of Aβ.  
Aβ peptides can also be generated intracellularly at different subcellular re-
gions whereas Aβ1-40 is generated solely in the trans-Golgi network (TGN), while 
Aβ1-42 is produced in the endoplasmic reticulum (ER) as well as in the Golgi com-
partments68,69. Aβ has also been found in mitochondria70,71. Although much of the 
intracellularly generated Aβ is enrolled to secretion, there is a significant pool of Aβ 
peptides that remain inside the cell. The pedigree of intraneuronal Aβ can be either by 
slow production of APP inside the neurons and/or taken up from the extracellular 
space. Several studies have described the internalization of Aβ from the extracellular 
pool72-75. In addition, stable Aβ oligomers are formed intracellularly in a variety of 
cell types, including primary human neurons71.  
 
Aβ pathology in Alzheimer’s disease 
In AD brain, amyloid exists in insoluble Aβ plaques (predominantly consisting of the 
40 or 42 amino acid residue), but also as diffuse plaques and pre-amyloid deposits as 
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well as additional forms of intracellular and extracellular soluble Aβ. It has been sug-
gested that fibrils, smaller peptide oligomers, water-soluble non-filamentous forms of 
Aβ might be toxic 76. The fibrillization of Aβ is a multistep reaction where Aβ mono-
mers assemble into oligomers. These oligomers further polymerize into protofibrils, 
which then mature into the Aβ fibrils that are found in the plaques 77. With the ad-
vancement of  the biomarker discoveries, it is now possible to measure fibrillar form 
Aβ in vivo using 11C PIB tracer with positron emission tomography (PET) technique 
even at prodromal stage of AD 78.  
Both in vitro and in vivo studies have shown that the purified Aβ oligo-
mers but not monomers can disrupt cognitive function79,80. There are three types of Aβ 
oligomers that have been identified in vitro: 1) very short oligomers ranging from di-
mer to hexamer size81; 2) Aβ-derived diffusible ligands (ADDLs)- small oligomers 
ranging from 17 to 42 kDa82; and 3) protofibrils, which can be seen in electron micro-
scopy as short fibril intermediates83. However, the unstable and diversity nature of 
these Aβ arbitrates, makes it difficult to identify the specific species of Aβ oligomers 
that is responsible for the neurotoxic effects in AD.  
Early cognitive impairment was manifested at 4-months of age in the triple 
transgenic AD mouse model, when NPs and NFTs are not present. This cognitive im-
pairment correlated with the accumulation of intraneuronal Aβ in the hippocampus 
and amygdala 84. In connection with intraneuronal Aβ, a number of studies have dis-
cussed the existence of intracellular Aβ accumulation in the brains of AD patients and 
animal models of AD and its impact on the pathogenesis of the disease such as synap-
tic impairment and neuronal loss85-90. This is in agreement with recent observation of 
a positive correlation between levels of isolated oligomers in autopsy AD brain and 
choline acetyltransferase (ChAT) activity and number of nicotinic receptors91, sup-
porting that the increased vulnerability of synaptic function caused by Aβ oligomers.  
 
The amyloid cascade hypothesis 
AD is considered to be a complex multifactorial disease and its definite disease me-
chanism is still under evaluation. Many theories have been proposed in the last century 
to explain the pathogenesis of AD. For explaining the disease process, one of the lead-
ing theories is the “amyloid cascade hypothesis.” According to this hypothesis, the 
brain accumulation of Aβ is the primary influence that triggers the cascade of patho-
genic events in AD, leading to the formation of NFT, inflammatory changes, and the 
loss of neurons and synapses in vulnerable regions that invariably accompany Aβ de-
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position92,93. Yet, this hypothesis remains controversial mainly because the specific 
neurotoxic species of Aβ and its effects on neuronal function in vivo have not been 
defined. It has long been assumed that Aβ had to be assembled into extracellular amy-
loid fibrils and accumulation into amyloid plaques to exert its cytotoxic effects; how-
ever, clinical studies have been unable to confirm a relationship between amyloid 
plaque load and dementia severity, or loss of neurons and synapses94,95. Moreover, 
numerous amyloid plaques that match the brain regional pattern of distribution seen 
in AD patients may also be present in many non-demented individuals96-98. Another 
argument against the amyloid hypothesis has been the observation that amyloid pla-
ques do not correlate as well with cognition scores as do neurofibrillary tangles99-
102.Therefore, a modified version of the amyloid hypothesis has been established 
which describes that it is soluble intraneuronal Aβ oligomers, not amyloid plaques 
that initiate the cascade leading to neuronal death and dysfunction103-105. Interestingly, 
recent discoveries are in agreement with the modified hypothesis, that the soluble Aβ 
oligomers rather than the actual plaques are more closely correlated to the clinical 
severity of disease and synapse loss106,107. An interesting observation is therefore, that 
APP arctic mutant AD patients show a reduction in Aβ1-42 in CSF as well as reduced 
cerebral glucose metabolisms but no presence of fibrillar form of Aβ in the brain 
measured by PET indicating that  high levels of oligomers, protofibrils are driving 
AD dysfunction108. 
An imbalance between production and clearance of the Aβ is a key momentum 
of the complex pathogenesis of AD. It is caused by overproduction of Aβ or by reduc-
tion of clearance from the brain. Clearance can be reduced by defective degradation, 
increased aggregation, disturbed transport across the blood-brain barrier or even ineffi-
cient peripheral removal of the peptide. Thus, entrapped Aβ in the brain undergoes ac-
cumulation and aggregation. 
 
Tau protein  
Tau proteins are a microtubule (MT) associated protein. The human tau is the product 
of alternative splicing from a single gene microtubule-associated protein tau (MAPT). 
It has six isoforms ranging from 352-441 residues with molecular weight of 45-
65kDa109. They are abundant in the neurons of the CNS and are less common in non-
neuronal cells, but are also expressed at very low levels in the CNS astrocytes and 
oligodendrocytes110. They are localized primarily in the distal portions of axons. In 
the normal brain, tau is necessary for stabilizing the MT network and regulation of 
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axonal transport111. Tau is a phosphoprotein, which has 79 potential Serine (Ser) and 
Threonine (Thr) phosphorylation sites on the longest tau isoform. Phosphorylation 
has been reported on approximately 30 of these sites in normal tau proteins. Tau can 
be post-transitionally modified by hyperphosphorylation, glycosylation, ubiquitina-
tion, glycation, oxidation, and proteolysis112-114.  
When tau is hyperphosphorylated, multi-steps of disorganization takes place 
such as: loss of the affinity of tau for the MTs115, dissociation of tau from MTs and 
thereby MTs disassembly, abnormal accumulation of tau in the somatodendritic com-
partment, impaired axonal transport, loss of synapses and finally neuronal cell 
death116,117.  The phosphorylation of tau is maintained by a mutual balance between 
kinases and phosphatases where kinases mostly cause phosphorylation of tau, and 
phosphatases do the opposite118. There are several kinases that are supposed to cause 
the tau hyperphosphorylation: the mitogen activated kinase (MAPK) family: extra 
cellular regulated kinase (ERK), P38 and c-Jun N-terminal kinase (JNK). However, 
the two major players for the hyperphosphorylation of tau are glycogen synthase ki-
nase-3β (GSK3β) and cyclin dependent kinase-5 (CDK5)119-121. 
 
Hyperphosphorylation of tau and formation of neurofibrillary tangles in  
Alzheimer’s disease 
The hyperphosphorylation of tau is the most extensively studied in AD pathology. 
There are some tau phosphorylation sites like Thr212/Ser214 (AT100) that are 
thought to be AD specific 122. Moreover, the severity of AD pathology has been cor-
related with some phosphorylating sites such as Ser202/Thr205 (AT8) and 
Ser396/Ser404 (PHF1), which showed strong signals in immunohistochemistry123. In 
the AD brain, tau is hyperphosphorylated and aggregated, forming paired helical fi-
laments (PHFs), which is the main component of NFTs124. The impairment of neu-
ronal function and cell death has been shown to be associated with the formation of 
NFTs. The number of NFTs seems to correlate more closely with the degree of neu-
ronal loss and decline of cognitive function as well as the severity of AD95,123,125. It is 
quite plausible that NFTs might be responsible for a neurotoxic cascade. Tau muta-
tions have been related to familial tauopathies other than AD, including frontotem-
poral dementia 126.  
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Interaction of Aβ and tau in AD 
Even though the Aβ is believed to be the major player of the disease process, tau pa-
thology is also strongly associated with the clinical expression and severity of AD99,101. 
In APP transgenic models, the manifestation of neurological deficits was evident before 
the deposition of significant amounts of Aβ1-42, suggesting that the pathophysiology of 
AD may occur prior to amyloid deposition98. AD is also considered to be a tauopathy 
as the brain develops abnormal aggregation of the tau protein 127,128. Despite the associ-
ation of the earliest AD symptoms with plaque pathology129, controversy has been gen-
erated by the association of clinical progression with tangles rather than plaques, and by 
the observation that tangles appear before Aβ deposition in the entorhinal cortex and 
the hippocampus130,131. Many studies agree that the amyloid cascade hypothesis me-
diates tau pathology as well as the association of Aβ to result in cognitive decline132. In 
addition, aggregated Aβ133, Aβ fibrils134, pre-aggregated Aβ135, oligomers 106 as well as 
dimers136 induced  tau hyperphosphorylation, microtubule disassembly, and finally neu-
ritic degeneration. On the other hand, reduced tau expression could block Aβ-induced 
cognitive impairments by reducing excitotoxicity in hAPP mice137, suggesting that tau 
reduction uncouples Aβ from downstream pathological mechanisms. In primary neu-
rons, tau was required for Aβ-induced microtubule disassembly138. A possible mechan-
ism involving tau phosphorylation was suggested by a study stating that intracellular 
Aβ binds to soluble tau and promotes tau phosphorylation by GSK3β which was further 
supported by co expression of Aβ and tau within tangles in postmortem AD brain139. 
Here the authors hypothesize that Aβ-tau complex generates insoluble composites of 
both Aβ and tau within the neuron, and suggest that the blockade of the Aβ-tau binding 
may be a viable therapeutic target. Another observation showed that Aβ and p-tau pa-
thology localize within the synaptic compartment in AD140. This also indicates the po-
tential target of early Aβ/tau interactions in the synaptic terminals. Furthermore, tangles 
can be found in the absence of plaques, while the same amount of plaques could be 
found both in AD and in non-demented elderly. 
 
NEUROTRANSMITTER SYSTEMS AFFECTED IN ALZHEIMER’S DISEASE 
The cholinergic neurotransmitter system is believed to play a key role in AD pathology 
141,142. Other neurotransmitter systems are also affected in AD. Along with cholinergic 
deficits, AD patients demonstrated deficits in other neurotransmitter systems such as 
dopaminergic, noradrenergic, serotonergic, and glutarmatergic neurons as well as sev-
eral peptide neurotransmitters. 
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THE CHOLINERGIC NEUROTRANSMITTER SYSTEM  
The cholinergic projections originate from the nucleus basalis of Meynert (nbM) and 
reach several cortical areas143. There are two main cholinergic tracts, the medial and 
lateral pathways to the cerebral cortex and amygdala. The medial pathway supplies the 
parolfactory, cingulate, pericingulate, and retrosplenial cortices. The lateral pathway is 
subdivided into the capsular and perisylvian divisions, the later innervating frontopa-
rietal operculum, insula, and superior temporal gyrus. The capsular division innervates 
the remaining parts of the frontal, parietal, and temporal neocortex.    
A number of studies in humans indicate that the cholinergic pathways serve 
important functional roles in consciousness, awareness, attention, and working mem-
ory144. The cholinergic system in the brain is important for higher cognitive functions 
including memory and attention, both of which are impaired in AD. The dysfunction 
cholinergic neurotransmission is comprised of a reduction in ACh synthesis due to 
reduced ChAT and choline uptake, cholinergic neuronal and axonal abnormalities, 
and degeneration of cholinergic neurons145. In conjunction with AD, it is evident that 
cholinergic neurons in the hippocampus and nucleus basalis are greatly reduced146. The 
degeneration of cholinergic neurons eventually causes the dysfunction of this system, 
which is considered to be one of the seminal features of AD. 
 
The cholinergic hypothesis 
Extensive studies of the brains of AD have consistently found damage or impairments in the 
cholinergic projections that appeared to correlate well with the level of cognitive decline. As a 
result, the “cholinergic hypothesis” was developed, which essentially states that a loss of cho-
linergic function in the CNS contributes significantly to the cognitive decline associated with 
AD141,142. A recent study has shown an association of high levels of fibrillar Aβ with losses of 
neuronal nAChRs in autopsy human brain supporting the hypothesis that neuronal nAChRs 
may play a critical role in AD pathology147. Based upon the cholinergic hypothesis, currently 
available clinical treatment of the ChE inhibitors was formulated. 
 
Cholinergic receptors 
Cholinergic neurotransmission is mediated by the interaction of ACh with two different 
types of receptors: mAChRs and nAChRs. The mAChRs are metabotrophic receptors, 
belonging to the G-protein coupled receptor family whereas the neuronal nAChRs are 
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transmitter /ligand gated ion channels, permeable to Na+, K+, and Ca+ ions and belong 
to the gene family of homologous receptors including NMDA, GABA, and 5-HT3 re-
ceptors.  
 The nAChRs have a pentameric structure and are composed of five membrane 
subunits consisting of α and β subunits148. Up to date, molecular biology studies have 
identified and cloned nine α (α2-α10) and three β subunits (β2-β4) of nAChRs in the 
rodent brain and eight nAChRs subunits (α3– α7, β2-β4) in the human brain Both α and 
β subunits preside over the pharmacological and functional properties of a defined sub-
unit composition i.e., channel open times, ion selectivity, and rates of desensitization149. 
The nAChRs have a sparse but widespread distribution in the human brain. They are 
located pre- and post-synaptically, and also at peri and extrasynaptic sites where they 
may regulate neuronal function by a variety of actions150-152. The most abundant sub-
types in the human brain are α4β2, α3β2, and α7 (homomeric) nAChRs.  
 
Normal function of nicotinic acetylcholine receptors 
The α7 nAChRs are thought to be involved in rapid synaptic transmission and play a 
role in learning153 and sensory gating 154. The α7 nAChRs subtype seems to play a 
role in the regulation of neuronal plasticity and differentiation during develop-
ment155 as well as neuroprotective mechanisms156-158.  
 
Nicotinic acetylcholine receptors in relation to Alzheimer’s Disease 
It is well known that nAChRs are closely related to cognition. Along with loss of choli-
nergic innervations, a severe loss of neuronal nAChRs, mainly in the cortical regions 
and the hippocampus has been reported 159-161. Both molecular and neurochemical lines 
of evidence link a selective loss of different subtypes predominantly α4β2 nAChRs, 
but also α3 and α7 subtypes in AD brains162-164 while α7 nAChRs are up-regulated in 
astrocytes50. This loss has been incorporated with in vivo PET studies indicating that 
deficits in nAChRs probably reflect an important step for the disease process of AD 
152,165. Moreover, it has been postulated that Aβ can bind to α7 nAChRs which might 
play a key role for the formation of Aβ plaque and degeneration of cholinergic 
neurons166. 
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Cholinesterases and their role in Alzheimer’s Disease 
There are two different cholinesterase (ChE) enzymes present in the human brain: ace-
tylcholinesterase (AChE) and butyrylcholinesterase (BuChE). AChE is present in the 
cholinergic nerve terminals -either intraneuronally, membrane bound or in the synaptic 
cleft (AChE-S), whereas BuChE is associated with glial cells or with neurons167. 
AChE comprises 90% of the total ChE in the temporal cortex of normal brain and me-
diates the inactivation of the most synaptic ACh47.  
A decreased activity of AChE, and a stable or increased activity of BuChE has been 
found in AD brain 47. Studies confirmed that AChE activity is intact in aged normal cerebral 
cortex168,169, but significantly reduced in the entire neocortex and the hippocampus of AD 
brains, even at the mild and moderate stages of the disease 168,170. With the progression of dis-
ease, a continued loss of AChE activity was detected, and the lower cortical k3 values corre-
lated significantly with the decline in memory and cognitive performances 170.  
 
 
THE GLUTAMATERGIC NEUROTRANSMITTER SYSTEM IN 
ALZHEIMER’S DISEASE 
L-glutamate is considered as the principal excitatory neurotransmitter in the mamma-
lian CNS acting upon a variety of receptor types 171,172. Glutamatergic neurons are 
widely distributed through the CNS, predominantly in the forebrain, where most of 
the cortical projections contain glutamate. There are two types of receptors that me-
diate the actions of glutamate: ionotropic receptors, which directly gate channels and 
metabotropic receptors, which involve signaling through messengers.  
 
The N-methyl-D-aspartate receptors in relation to Alzheimer’s disease 
N-methyl-D-aspartate (NMDA) receptor is one of the major types of ionotropic glu-
tamatergic receptors. The NMDA receptor is a heterogenic ligand-gated ion channel 
that interacts with multiple intracellular proteins by way of different subunits- namely 
NR1, NR2A-D, and subunits- namely NR1, NR2A-D and NR3A-B with different 
splice variants 173,174. These receptors are involved in a variety of neural processes, 
including long-term potentiation (LTP) 175,176, long-term depression (LTD)177,178, 
brain development, excitotoxicity179, learning, and memory180,181. Prolonged activa-
tion of NMDA receptors results in excessive Ca2+ influx that can trigger excitotoxic 
signaling that propagates neuronal death, glutamate release, and subsequent apoptosis 
of neuron in hypoxia, ischemia, and neurodegenerative disorders such as AD 182,183. 
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Altered glutamate levels and loss of NMDA receptors are evident in post-mortem AD 
brain183,184. Recent studies revealed that NMDA receptors play a critical role in the Aβ 
induced neurotoxicity especially Aβ1-42 185,186,  but also Aβ1-40 187. It has been shown 
that stable Aβ oligomers decrease cell surface expression of  NMDA receptors there-
by inhibiting the induction of LTP, facilitate the LTD, alter dendritic spine density, 
and affect hippocampal synaptic plasticity79,82,188-193. Moreover, Aβ mediates and 
promotes NMDA receptor endocytosis possibly via the α7 nAChRs193.  
 
EPIGENETICS  
Epigenetics refers to the heritable modifications in gene function or activity without 
changes in the DNA nucleotide sequence194. Epigenetic processes are genetic modifi-
cations that affect gene regulation by changing the DNA conformation. Therefore, 
gene function of any organisms is not only determined by the DNA code but also by 
the epigenetic phenomena. The epigenetic modifications can be carried out by histone 
modification or DNA methylation. 
 
 
Histones 
Within the chromosome, DNA is packaged by chromatin. This structural unit of chro-
matin is called nucleosome 195. Nucleosomes are made up of 146 base pairs of double-
stranded DNA wrapped around the core complex of 8 histones196. This core complex 
consists of two copies of each of the histone proteins H2A, H2B, H3, and H4, orga-
nized as a central (H3-H4)2 tetramer flanked by two H2A-H2B dimers197. Histones are 
small basic proteins of 102-135 amino acids and their main function is to package the 
genomic DNA into nucleosome198. Each core of histone protein has two domains: a 
histone fold domain or globular domain, which is involved in histone-histone interac-
tions as well as in packing DNA in nucleosomes; and a more flexible and charged 
amino-terminal ‘tail’ domain of 25-40 residues 199. The tail lies on the outside of the 
nucleosome where it can interact with other regulatory proteins and with DNA. The 
basic N- terminal tails of the core histones act as signal integration platforms, where-
by post-translational modifications are combined in a ‘histone code’ 200,201.  
The histones (H3-H4)2 tetramer are modified by acetylation (AC), me-
thylation (Me), and phosphorylation (P); and H2A-H2B dimers are modified by ace-
tylation, phosphorylation, ubiquitination (Ub), multiubiquitination, and ADP-
ribosylation. The function of these modifications is important due to the possibility 
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that the nucleosome, with its modified tail domains, is not only a packer of DNA but 
also a carrier of epigenetic information. This indicates how genes are expressed as 
well as how their expression patterns are maintained from one cell generation to the 
next.  
 
Histone acetylation 
Acetylation of histone (Ac) is an enzymatic process by which inert chromatin is activated for 
RNA transcription202. A positive charge on lysine (Lys) residues of core histones is restored 
by histone deacetylation, permitting chromatin to change into a highly condensed, transcrip-
tionally silent conformation or heterochromatin. Therefore, in most cases, histone acetylation 
permits transcription while histone deacetylation represses transcription. Nevertheless, in 
some cases transcriptional repression occurs as a result of histone acetylation. The balance 
between histone acetylation/deacetylation is controlled by the competitive activities of 2 su-
perfamilies of enzymes: histone acetyltransferases (HATs) and histone deacetylases 
(HDACs)203,204. Acetylation of the histone tails might permit the access of transcription fac-
tors to DNA as well as assembly of nucleosome . H3 and H4 acetylation release a fraction of 
nucleosomal DNA from the packing of the nucleosome in vitro205. Therefore, different dis-
eases can be the result of hyperacetylation of chromosomal regions that are generally silenced 
or deacetylation of chromosomal regions that are generally actively transcribed. 
 
Histone methylation and ubiquitination 
Similar to acetylation, methylation of histones also occurs on Lys residues, and is 
mediated by histone methyltransferases (HMTs)206,207 while ubiquitylation occurs 
through the attachment of a ubiquitin to the Lys residues208.  
 
Histone phosphorylation 
Histone H3 was the first histone whose phosphorylation was characterized in re-
sponse to the activation of mitogenic signaling pathways209. Phosphorylation of serine 
10 on H3 is mediated by ribosomal protein S6 kinase 2210. In addition, extra cellular 
signal-related kinase (ERK), mitogen activated protein kinase (MAPK), phosphatases 
PP1, and PP2A have been shown to regulate the phosphorylation of H3211-213. H3 ace-
tylation and phosphorylation are thought to be partly interdependent. 
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Epigenetics in relation to memory formation and Alzheimer’s disease 
Memory is a process that is utilized by the brain for the long-term storage of informa-
tion. Several studies have implicated that the formation of long-term memories is a 
complex process that can be mediated by many signaling pathways and the regulation 
of numerous genes214,215. Subsequent studies suggested both transcription and transla-
tion are important for the formation of long-term memories216-218. Acetylation of his-
tone H3 was significantly increased after an animal underwent contextual fear condi-
tioning- a hippocampus dependent learning model. This observation was the first in-
dicator that epigenetic tagging of the genome occurs during consolidation of long-
term memories219. The histone deacetylase inhibitors (HDACis), which cause histone 
acetylation, facilitated learning in rodents220,221. Another study also showed the in-
volvement of H3 phosphorylation in memory storage222.  These findings indicate that 
there might be a histone code for memory formation. The acetylation of H4, but not 
H3 was reduced in APPswe mice, a model of amyloid pathology 223. Interestingly, 
administration of the pan-HDACi phenyl-butyrate was able to restore associative 
memory function and synaptic plasticity in APPswe mice223,224 as well as in 
APP/PS1D9 mice, both of which are models for AD225. These findings suggest that 
histone acetylation is increasingly important as one of the key mechanisms to regulate 
gene-expression programs that are required for learning and memory. Consistent with 
mentioned findings, human autopsied brain studies indicate that the epigenetic marks at 
the DNA and histone level are modulated in relation to numerous insults associated 
with AD226,227.  
 
MOUSE MODELS RELATED TO ALZHEIMER’S DISEASE 
The definite path of the disease mechanism of AD is still not fully understood. This is 
because all the molecular mechanisms are not always accessible for studying purpos-
es in living humans. In this regard, the development of animal models has been a re-
search priority to understand the pathogenesis and to test therapeutic strategies.  
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Table 1: Characteristics and neuropathological features of several transgenic mouse models for 
AD 
 
Name Transgene Aβ dep. NFT Neuron loss Gliosis Reference  
APPswe 
APP695  
(K670N/M671L) 9 months 
No  
(but AT8 
IR) No Yes 228 
hAChE-Tg 
Overexpression 
of  human AChE No No 
Attenuated 
dendritic 
branching, 
reduced spine 
numbers 
Not re-
ported 229 
hAChE-Tg 
//APPswe 
Overexpression 
of human AChE 
+ APP695 
(K670N/M671L) 6 months 
Not re-
ported Not reported Yes 230 
APP23 
APP751 
(K670N/M671L) 6 months 
No  
(but AT8 
IR) Yes Yes 54 
PDAPP 
APP695, 751 and 
770 (V717F) 
6-9 
months 
No  
(but AT8 
IR) No Yes 231 
 
TgAPParc APP695 cDNA 
(E693Q) 4  months 
Not re-
ported Not reported 
Not re-
ported 
Ronnback, 
Zhu et al. 
2011 
TgArcSwe APP695 cDNA 
(K670N/M671L, 
E693Q) 
6 months No  
(but AT8 
IR) 
Not reported Not re-
ported 
232 
APP/PS1KI 
APP751 
(K670N/M671L, 
V717I) + PS1 
(M233T, L235P) 
2.5 
months No Yes Yes 233 
TAPP 
APP695 
(K670N/M671L) 
+ tau (P301L) 6 months 
9-10 
months Yes Yes 234 
3xTg-AD 
APP695 
(K670N/M671L) 
+ PS1 (M146V) 
+ tau (P301L) 6 months 15 months Not reported Yes 84 
5xFAD 
First transgene 
hAPP695 swe 
(K670N/M671L), 
Florida (I716V) 
and London 
(V717I); 
Second trans-
gene: hPS1 
(M146L and 
L286V) mutation 
1.5-2 
months  Yes Yes 235 
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Among the animal models, mice offer several advantages in scientific research. They 
are small and easy to rear.  Their progeny are abundant and they have very short ges-
tation; furthermore, their size makes them manageable and, most notably, their whole 
genome has been mapped. The discovery of genes for FAD has allowed transgenic 
mouse models to be generated through the overexpression of the APP and/or preseni-
lins harboring one or several mutations found in FAD. Although none of the trans-
genic mice reproduces the human condition exactly, they serve as important tools al-
lowing for the study of similar pathological processes in vivo, which has provided 
valuable insights into disease mechanisms and opportunities to test therapeutic ap-
proaches. In addition, many of them develop amyloid pathology such as deposition of 
Aβ plaque and this feature depends on different factors such as single or multiple 
harboring mutations in APP or PS genes, promoter for driving over-expression of 
gene, and integration site and also the genetic background of the mice. In these mice, 
Aβ plaque appears ranging from 2.5 to 15 months of age. Conversely, studies on htau 
mice indicated that tau pathology might trigger an age-dependent learning impairment 
via disruption of synaptic function236. The main characteristics and neuropathological 
features of a number of transgenic mouse models are shown in Table 1. The transgen-
ic mouse models of AD have also provided the key roles of soluble Aβ oligomers in 
the pathogenesis of disease as well as of the relationship between Aβ and tau pathol-
ogies. A significant number of studies of different AD mouse lines indicate that the 
onset and the severity of the Aβ deposits are directly linked to the level of soluble 
Aβ1-42 peptide 84,96,237-240. In addition, different studies of AD-related transgenic mice 
indicate that intraneuronal Aβ1-42 triggers early neuronal loss as well as synaptic defi-
cits84,235 which is in agreement with the hypothesis that synaptic loss is one of the ear-
liest events in AD pathogenesis241,242. Furthermore, evidence from AD transgenic 
mouse models supports the concept that Aβ may directly or indirectly interact with 
tau to accelerate NFT formation234,243. Altogether, AD transgenic models may allow 
to understand the molecular interactions of the disease pathogenesis in vivo as well as 
to evaluate potential therapeutic targets as well as to develop therapeutic strategies 
that might interfere or delay the disease progression. 
 
THERAPEUTIC STRATEGIES OF ALZHEIMER’S DISEASE 
The first clinically available and also present used treatment therapy in AD was  
based upon the cholinergic hypothesis . The advancement of understanding the com-
plex molecular pathogenesis of AD, has resulted in a number of tentative therapeutic 
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interventions (Fig 2). However, AD is a complex multifactorial disease, therefore, the 
complete curative treatment is still a burning question. 
 
Neurotransmitter therapy 
The current available medications for AD include three different   ChEIs and the 
NMDA receptor antagonist- memantine. Although they produce modest effect they 
also provide cognitive benefits to the patients.  
 
 
 
 
 
Figure 2. Schematic illustration of present and possible future therapies for AD  
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Cholinesterase inhibitors 
Three ChEIs are available for treating mild to moderate AD patients (Fig 2). All these 
drugs inhibit AChE, a degrading enzyme of ACh, thereby increasing the concentration 
of ACh in the synaptic regions. This in turn, enhances and prolongs the actions of ACh 
to its receptors to improve cognitive function155. These drugs provide symptomatic im-
provement for several years but not prevent the disease progression. Several PET stu-
dies in patients treated with cholinesterase inhibitors have shown a significant correla-
tion between cognition and cholinesterase activity, number of nicotinic receptors and 
cerebral glucose metabolisms244-246. 
 
N-methyl-D-aspartate receptor antagonist 
Memantine is a specific non-competitive, moderate –affinity NMDA receptor antagon-
ist247,248. According to different meta-analysis, memantine was shown to be effective in 
moderate to severe AD, slightly improving cognitive and global status but there was no 
improvement in function or behavior249-251. 
 
 
Targeting Aβ 
The search of disease modifying interventions has focused largely on the compound 
targeting the Aβ pathway aiming to reduce Aβ load in the brain. There are several 
strategies targeting Aβ are under therapeutically evaluation. One such approach is to 
inhibition of Aβ production by inhibitors of β-secretase and γ-secretase. Pioglita-
zone252 and rosiglitazone253 drugs for diabetes mellitus could also down regulate β-
secretase and APP. Semagacestat, a γ-secretase inhibitor has been studied extensively 
in AD trials 254. However, these drugs have been discontinued after failure to demon-
strate efficacy. Another approach to target inhibition of Aβ aggregation is by inhi-
biting Aβ assembly to Aβ oligomers and fibrils, which would prevent Aβ toxicity. 
Clioquinol (PBT-1)255, PBT-2256, glucosaminoglycans [tramiprosate (NC-531)]257, 
have all been suggested as possible therapies. Removal of toxic aggregated Aβ de-
posits from the brain thereby to attenuate the detrimental effects of AD is another the-
rapeutic approach by using active or passive immunization. In 1999, Aβ immuniza-
tion in PDAPP transgenic mice, prevented the plaque formation and astrogliosis as 
well as reduced the extent and progression of AD-like pathologies258. These preclini-
cal observations led to the first clinical trial using active immunization with Aβ1-42. 
However, the trial was halted due to serious adverse events of meningoencephalitis in 
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6% of treated patients259. Passive immunization with anti-Aβ monoclonal antibodies 
has also been tested in clinical trials. It is estimated that approximately 20 different 
antibodies for passive or active immunization are presently under clinical trials in AD 
patients. So far no clinical benefits on cognition have been reported although reduc-
tion in fibrillar Aβ plaques have been reported in brain by PET260 as well as in post-
mortem examinations261. 
 
Targeting tau 
Inhibition of tau hyperphosphorylation and promotion of filament 
disassembly account two viable strategies for disease-modifying therapies 262. In this 
regards, inhibitor of major tau phosphorylating kinase GSK3β and dissolving tau fila-
ments by methylthioninium chloride are being considered. Neither lithium263  nor val-
proate264 was able to show significant improvements. This effort could be complicated 
due to the large number of tau phosphorylation sites, the unknown role of individual 
phosphorylation sites in disease pathogenesis and  also the ability of multiple kinases to 
phosphorylate individual sites 265.  Recently an active immunization against the patho-
logical phosphor-tau epitope phospho-Ser422 was performed in 3months old THY-
Tau22 transgenic mouse model, which exhibit hippocampal NFT-like inclusions and 
display phosphorylation of tau on several AD-relevant tau epitopes. There was a de-
crease in insoluble tau species which correlated with a significant cognitive improve-
ment in the Y-maze 266.  
 
Other therapies  
Different epidemiological studies of drugs have shown that the risk of AD is decreased 
by long-term treatment with cholesterol-lowering drugs 267, non-steroidal anti-
inflammatory drugs (NSAIDs) 268 and estrogen269. However, none of these have drugs 
have been shown to treat AD patients. Different epidemiological studies of drugs have 
shown that the risk of AD is decreased by long-term treatment with cholesterol-
lowering drugs 267, non-steroidal anti-inflammatory drugs (NSAIDs) 268 and estro-
gen269. However, none of these have drugs have been shown to treat AD patients. Sev-
eral other epidemiological studies have also demonstrated that social activity, physical-
ly active people, and even consumption of Mediterranean diet have low risk to develop 
AD270,271. Therefore, in future there is possible to formulate new therapeutic preven-
tive strategies. 
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Several treatment strategies focusing on neuroprotective mechanisms 
are of interest.  As already discussed α7 nAChR may play a vital role in AD would be 
a potential therapeutic approach272. Regenerative mechanisms induced by drug or cell 
transplantation increasing neurogenesis might be tentative new treatment strategies in 
the future273,274. 
There are different other strategies for treating AD patients. Inducing neu-
roprotection would be one tentative approach. As discussed earlier that α7 nAChR play 
a vital role in AD and has been found within and around the plaque50. Experimental 
studies showed that α7nAChR agonists could reduce Aβ related toxicity thereby it 
would be a potential therapeutic approach.  
 Nerve growth factor (NGF) stimulates growth of cholinergic neurons and 
showed neuroprotection in different neurodegenerative disorders. NGF infusion275 or 
NGF implantation276 in nucleus basalis Meynert of mild AD patients improve might 
be a possible strategy to improve brain function. 
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AIM OF THE THESIS 
The general aim of the present work was to study changes of Aβ isoforms in relation to 
different ages of transgenic mouse models and to gain further insight into how different 
Aβ isoforms influence the phosphorylation of tau, inflammatory processes and synaptic 
function how different cholinergic drugs could  affect Aβ processing.  
 
SPECIFIC GOALS: 
• To elucidate different forms of Aβ and their effects on synapses, α7 
nAChRs and NMDA receptors, as well as to evaluate whether these effects 
are mediated via the ERK/MAPK signaling pathway at different ages of 
APPswe mice (Paper I). 
 
• To investigate the effects of Aβ, under the constant influence of AChE, on 
synapses, α7 nAChRs and glial cells in hAChE-Tg//APPswe double trans-
genic mice. (Paper II) 
 
• To characterize the consequences of Aβ isoforms in relation to different ages 
of APPswe mice and to explore if these Aβ isoforms have any effect on 
phosphorylation of tau, GSK3β and CDK5 (Paper III) 
 
• To examine the consequences of the excess of Aβ on epigenetic changes, es-
pecially the regulation of histones in APPswe mice, APPswe transfected SH-
SY5Y cells and human post-mortem brain tissue from AD patients. (Paper 
IV) 
 
• To study the effects of treatment with different cholinergic drugs on modula-
tion of amyloid processing in SH-SY5Y cells transfected with APPswe mu-
tation. (Paper V) 
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MATERIALS AND METHODS 
 
Table 2: Schematic illustration of different materials and methods  that have been used in the dif-
ferent papers.  
 
Paper                 Subject Treatment           Parameter 
        
 
      I 
• APPswe mice at ages 
7, 21 and 90- days 
 
 
            NO 
• Aβ ELISA 
• Synaptophysin (WB) 
• sAPPα (WB) 
• [125I]α-bungarotoxin 
autoradiography 
 
 
    II 
• hAChE-Tg/APPswe 
mice at ages 1, 3, 10- 
months used for base-
line 
 
• 14- months of age 
used for treatment 
 
 
• (+)-Nicotine 
• (-)-Nicotine 
• Aβ and GFAP ELISA  
• GFAP  (IH) 
• Synaptophysin (WB)  
• [125I]α-bungarotoxin 
 
 
       
   III 
 
• APPswe mice oat ages 
7, 21, 90- day and 15-
months 
 
 
 
              NO 
 
• Aβ MALDI-TOF MS 
• Aβ oligomers (WB) 
• tTau & pTau (WB) 
• GSK3 and CDK5 
(WB)  
 
 
 
 
    IV 
• APPswe mice of  4- 
month-old 
• Postmortem brain 
from AD subjects 
• SH-SY5Y/APPswe 
cell line (treatment) 
 
 
 
• DAPT, 
• NaB 
• Aβ Mesoscale ELISA 
• TH3, AcH3, PH3, and 
2MeH3 (WB) 
• AcH3 and NeuN (IH) 
 
       
 
   V 
• SH-SY5Y/APPswe 
cell line 
• HEK293/APPswe cell 
line 
 
• Nicotine 
• JN403 
• Varenicline 
• Galantamine 
• (+)-Phenserine 
• (-)-Phenserine 
• Aβ  ELISA 
• sAPPα ELISA 
• sAPPβ ELISA 
 
 
SUBJECTS 
 
Animals (Paper I, II, III, IV) 
All the housing and laboratory measures were followed according to the principles of 
Laboratory Animal Care (National Institutes of Health, publication 86-23, revised 
1996). All animal experimental protocols were approved by the local Ethics Committee 
and carried out in accordance with the guidelines of the Swedish National Board for 
Laboratory Animals (CFN) (Dnr S82/01, S128/04, S81/01, S129/04, and S43/07). All 
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mice that were bred, born in our own colony and housed under the same conditions 
with an enriched environment, controlled temperature and humidity, and a 12 h 
light/dark cycle. The mice had access to food and water ad libitum. Offspring were 
marked and weaned at 21 days and housed alone (male) or with 1–4 siblings of the 
same sex (female) in standard laboratory Plexiglas cages (30 × 20 × 15 cm), with wood 
shavings provided as bedding material. The cages and bedding material were changed 
twice a week. All mice used in the studies were sacrificed by decapitation during the 
daytime. 
 
APPswe mice (Papers I, II, III and IV) 
Two female transgenic mice over-expressing APP695, containing a KM670/671NL 
mutation driven by a hamster prion protein gene promoter in a C57B6 × SJLF1 hybrid 
mouse, back-crossed to C57B6 mice 228, were kindly provided by Prof. Karen Hsiao-
Ashe. C57B6 mice (Bomice & Mollegard Breeding Laboratories, Denmark) were used 
to breed a colony of experimental animals (Papers I, II and III). 7-day to 15- month old 
animals were used to carry out different experimental measures (see Table 2). 
 APPswe mice used in Paper IV were bred and studied at the University of Bir-
mingham, AL, USA.  
  
hAChE-Tg//APPswe mice (Paper II) 
To breed a colony of double transgenic(hAChE-Tg//APPswe) mice, male APPswe 
transgenic mice and female FVB/N mice carrying human AChE cDNA 229(hAChE-Tg 
mice: two females were kindly provided by Prof. Hermona Soreq, were used to breed 
our own colony of hAChE-Tg mice) were used. The control for this transgenic line was 
used as offspring of C57B6 mice crossed with FVB/N mice (Bomice & Mollegaard 
Breeding Laboratories, Ejby, Denmark).  
 
Cell culture (Paper IV and V) 
Human neuroblastoma SH-SY5Y cells and human embryonic kidney HEK293 cells 
stably transfected with human APP Swedish KM670/671NL double mutations were 
kind gift from Dr. Erikur Benedikz277,278. The cells were cultured in RPMI 1640 + Glu-
tamax I media supplemented with 10% fetal calf serum and 0.05% gentamycin. The 
cells were grown in 5% CO2 humidified incubator at 37οC. 
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Human postmortem brain tissue (Paper iV) 
Brain tissues of both AD and control subjects were obtained from the Netherland Brain 
Bank (NBB) (Amsterdam, the Netherlands). The clinical diagnosis of dementia was 
performed according to NINCDS-ADRDA criteria 39 and its severity was estimated 
according to the Global Deterioration Scale 279. For selecting the control subjects, all 
other neurological or psychiatric disorders were excluded.  
 
DRUG TREATMENTS (PAPERS II, IV AND V) 
The two enantiomers of nicotine (Paper II) 
Fourteen-month-old hAChE-Tg//APPswe mice and non-transgenic control mice were 
included to the treatment with L(-)-nicotine or D(+)-nicotine twice daily (at 8:00–9:00 
and at 16:00-17:00) (s.c.) for 10 consecutive days. The doses of D(+)- and L(-)-nicotine 
were gradually increased from 0.20 mg/kg (free base) on day 1, 0.30 mg/kg on day 2 
and 0.45 mg/kg on days 3–10. The drugs, dissolved in sterile 0.9% NaCl, were freshly 
prepared for each injection session.  
 
LY-374973 and Sodium Butyrate (paper IV) 
LY-374973, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-sphenylglycinet-butyl ester 
(DAPT)  was prepared in DMSO (vehicle) at a concentration of 100 μM and treated for 
16 h. Sodium butyrate (NaB) was prepared in ultra-pure H2O (vehicle) at a concentra-
tion of 400 μM and treated for 4 h. Human neuroblastoma SH-SY5Y/APPswe and 
wild-type cells were used for both drug treatments. 
 
Cholinergic substances (paper V) 
HEK293/APPswe and SH-SY5Y/APPswe cells were used to treat with nicotine, galan-
tamine, (-)-phenserine, (+)-phenserine, JN403 and varenicline for 72 h at serial concen-
trations ranging from 10-9 to 10-5M. The drugs were prepared in ultra-pure H2O (ve-
hicle) at a concentration of 10-3M and further diluted in complete media for the treat-
ment purpose.  
 
EXPERIMENTAL METHODS 
ELISAs 
Levels of Aβ1–40 and Aβ1-42 (Papers I, II, III and IV) 
Homogenates were prepared from the dissected cortices with ice-cold homogenate 
buffer in 1:7 volumes (w/v) of 20 mM Tris-HCl buffer (pH 8.5) containing protease 
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inhibitor cocktail  (Roche, Basel, Switzerland) (Papers I and II). The brain homogenate 
solution was then centrifuged at 100,000 × g for 1 h at 4ºC. The supernatant was diluted 
with phosphate-buffered saline (PBS) including bovine serum albumin (0.5 %), Tween 
20 (0.05%) and protease inhibitor cocktail (standard buffer) to appropriate concentra-
tions and this represented the Tris-extracted (soluble) Aβ fraction. The remaining pellet 
was extracted in 10 volumes of 5 M guanidinium-HCl in 20 mM Tris-HCl (pH 8.0) for 
1.5–2 h at room temperature, diluted 1:5 with standard buffer and centrifuged at 13,100 
× g for 20 minutes at 4ºC. The obtained supernatant represented the guanidinium-
extracted (insoluble) Aβ fraction.  
 Dissected brain cortices were homogenized in ice-cold homogenate buf-
fer [containing 50 mM Tris, 1 mM EGTA and EDTA, protease inhibitor cocktail 
(Sigma), phosphatase inhibitor 1 and 2 (Sigma), sodium butyrate and PMSF] and cen-
trifuged at 16,000 g at 4 ° C for 30 min. The supernatants were used as Tris-extracted 
Aβ fraction (Paper III). 
The media from drug as well as vehicle-treated HEK293/APPswe and 
SH-SY5Y/APPswe cells were used for measuring the amount of releasing Aβ1–40 and 
only SH-SY5Y/APPswe cells were used for measuring Aβ1–42 (Paper V). 
The levels of Aβ1–40 and Aβ1–42 peptides were analyzed by using Signal 
Select™ Human β-Amyloid 1–40 and 1–42 colorimetric sandwich ELISA kits (Bio-
Source International Inc., Camarillo, CA, USA) according to the manufacturer’s proto-
cols. Concentrations of Aβ1–40 and Aβ1–42 were calculated by comparison with standard 
curves of synthetic human Aβ1–40 and Aβ1–42, respectively.  
 
GFAP immunoreactivity (Paper II) 
For measurement of GFAP immunoreactivity, hippocampal tissue from mouse brain 
was homogenized in 1% sodium dodecyl sulfate (SDS). A DC protein assay kit (Bio-
Rad, Stockholm, Sweden), using bovine serum albumin as a standard, was used to 
measure the protein content in the fractions. 
A polyclonal GFAP antibody (1:400: Z0334, DakoCytomation, Glostrup, Den-
mark) was used to coat the wells of microtiter plates. After blocking non-specific bind-
ing with non-fat dried milk, aliquots of the SDS homogenates were diluted and added 
to the wells. Following appropriate blocking and washing steps, a monoclonal GFAP 
antibody (1:500: IF03L, Calbiochem, USA) was added to the “sandwich”. An alkaline 
phosphatase-linked IgG antibody (1:3000) was then added and a colored reaction prod-
uct was obtained by subsequent addition of enzyme substrate. Spectrophotometric ab-
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sorption at 405 nm was measured and expressed as GFAP immunoreactivity/mg total 
protein 
 
sAPPα and sAPPβ release (Paper V) 
Secreted forms of APPα and APPβ from the media of drug-treated SH-SY5Y/APPswe 
cells were measured using highly sensitive human sAPPα and human sAPPβ-swe colo-
rimetric sandwich ELISA kits (Immuno-Biological Laboratories Co., Ltd. Fuji-
oka, Gunma, Japan). The experiments were performed according to the manufacturer’s 
protocol. Samples were diluted 4X with EIA buffer (included in the assay kit) and 
plated in duplicates. All the samples were analyzed in the linear range of the standard 
curve of the ELISA. 
 
Mesoscale ELISA (Paper IV) 
Three different species of Aβ: 1-38, 1-40 and 1-42 were measured in media using a 
MULTI-SPOT human (6E10) Aβ Triplex Assay kit (Mesoscale Discovery, Gaithers-
burg, Maryland, USA) according to the manufacturer’s instruction.  
 
Immunoprecipitation and Mass Spectrometry (Paper III) 
The dissected brain cortices (30–80 mg) were homogenized in ice with 1:5 volumes 
(w/v) Tris-buffered saline (20 mM Tris, 137 mM NaCl, pH 7.6) containing complete 
protease inhibitor cocktail (Roche, Basel, Switzerland). Formic acid (FA) was added 
to the sample (final concentration 70%) followed by sonication (power: 15 amplitude 
microns; tune: ‘middle’) and centrifugation at 30,000 g for 1 h at 4 ° C. The FA-
soluble Aβ extract was dried and dissolved in FA, and finally neutralized using 0.5 M 
Tris. Immunoprecipitation (IP) using the KingFisher magnetic particle processor 
(Thermo- Scientific, Waltman, Mass., USA) and mass spectrometric analysis using 
MALDI-TOF MS were performed. An aliquot (8 μg) of the anti-Aβ antibodies 6E10 
and 4G8 (Signet Laboratories, Dedham, Mass., USA), which is reactive to amino ac-
ids 1–17 and 17–24, respectively, was separately added to 50 μl each of magnetic 
Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen, Carlsbad, Calif., USA). The 
6E10 and 4G8 antibody coated beads were mixed and added to 5–10 μl brain homo-
genates, and diluted to 1 ml in 0.025% Tween 20 in PBS (pH 7.4). After washing by 
using the KingFisher magnetic particle processor, the Aβ isoforms were eluted using 
100 μl 0.5% FA. MALDI-TOF MS measurements were performed using an Autoflex-
instrument (Bruker Daltonics, Bremen, Germany) operating in linear mode at 19 kV 
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acceleration voltages. Each spectrum represents an average of 1,500 shots acquired 
75 at a time. The MALDI samples were prepared with the seed layer method using α-
cyano-4-hydroxycinnamic acid as the matrix. Each isoform in the 
spectra were normalized to the sum of all isoforms in the spectra. This kind of data 
shows the relative changes of all the different isoforms in response to age.  
 
Immunoblotting (Paper I, II, III and IV) 
Tissue preparation for APP, Synaptophysin, ERK (Paper I) 
Homogenates of brain cortical tissue were prepared in ice-cold buffer of 20 mM Tris-
HCl (pH 8.5), containing protease inhibitor cocktail (Roche, Basel, Switzerland) (for 
ERK and phospho-ERK 1: mM EG/EDTA, 1 mM Na4P2O7, 1 mM Na3VO4, 0.1 mM 
PMSF, 0.1 mM PNPP-PP2b and 1 µM Microcystin-LR were added), followed by cen-
trifugation at 60,000 × g for 20 minutes. The obtained supernatant represented the cyto-
solic fraction. The remaining pellets were re-suspended in ice-cold homogenate buffer 
with the addition of Triton X-100 (2%). The suspension was mixed for 2 h at 4 ºC fol-
lowed by centrifugation at 100,000 × g for 1 h. The obtained supernatant represented 
the membranous fraction. A DC protein assay kit (BioRad) was used to measure the 
protein content in the different fractions. 
 
Tissue preparation for tau and tau-related kinases (Paper III) 
Dissected brain cortices were homogenized in ice-cold homogenate buffer [containing 
50 mM Tris, 1 mM EGTA and EDTA, protease inhibitor cocktail (Sigma), phospha-
tase inhibitor 1 and 2 (Sigma), sodium butyrate and PMSF] and centrifuged at 16,000 
g at 4 ° C for 30 min. The supernatants were used as cytosolic fraction (Paper III). 
 
Tissue preparation for histone H3 and AcH3, PH3, and 2MeH3 (Paper IV) 
All procedures were performed at 4° C unless otherwise indicated. Using Dounce ho-
mogenizers, brain tissue from APPswe  and control mice as well as human or cells 
were homogenized in 50 mM Tris (pH 7.5) containing 250mM sucrose, 25mM KCl, 
0.5mM phenylmethylsulfonyl fluoride, 0.9 mM NaB and protease and phosphatase in-
hibitors (Sigma). Subsequently, the combined nuclear and membrane fraction was pel-
leted by centrifugation at 7,700 x g for 1 min. The histone fraction was acid-extracted 
from the pellet by re-suspension and incubation in 0.4 N H2SO4 for 30 min. The re-
suspension was centrifugation at 14,000 g for 10 min and the supernatant collected. 
Histone proteins were precipitated from the supernatant after adding 0.004% deoxycho-
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late in trichloroacetic acid for 30 min. Precipitated histones were pelleted by centrifuga-
tion at 14,000 x g for 30 min, then washed with acidified acetone (0.1% HCl) followed 
by 100% acetone in the same manner. The crude histone pellet was res-uspended in 50 
mM Tris (pH 8.0) and total protein concentration was quantified using the Bradford 
assay.  
 
Experimental procedure for immunoblotting 
Standard procedure was carried out for the experimental purpose. Briefly, extracted 
proteins were size-fractionated by SDS-PAGE in the corresponding gel type (see Table 
3). After electrophoresis, (1) PVDF membranes were processed and (2) blocked either 
in 3-5% serum albumin (BSA) or non-fat dried milk dissolved in TBS-T solution (3) 
incubated with primary antibody either for 1 h at RT or overnight at 4ºC (Table 3) (6) 
incubated with secondary antibody (4) exposed in ECL Plus reagents, (5) exposed to 
film (6) developed.  
 
Image analysis 
The Western blot films were scanned using a Sharp JX-325 scanner (Papers I and II) or 
by using a high-resolution scanner (Canon CanoScan 5200F, Papers III and IV). The 
OD values of the bands were calculated as a product of contour OD and the area of the 
contour using Image Master 1D software (version 1.10; Pharmacia Biotech: Papers I 
and II) or by using Image J (Paper III and IV). As regards,  phospho-ERK1/2, phospho 
tau, phosphor-GSK3β and CDK5 band intensity were first normalized to the band in-
tensity detected with corresponding total protein, and then all samples were standar-
dized to the pooled sample (paper I, II) or β-actin (paper III) allowing comparison be-
tween groups.  
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Table 3: Gel types and antibodies used for immunoblotting assay in different papers 
 
Paper       Gel type Antibody Epitope(s) Dilution Source 
      
     I 
12-well 4–20% 
gradient 
 
 22C11 
6E10 
Synaptophysin 
Total ERK 
Phospho ERK 
 
Total sAPP 
Human sAPPα 
 
 
Thr202/Tyr204 
1:1000 
1:500 
1:2000 
1:1000 
1:3000 
Chemicon 
Chemicon 
DakoCytomation 
BioSource 
Cell Signalling 
     II 12-well 10% 
Tris-HCl 
mini gel 
 
Synaptophysin  1:2000 
 
DakoCytomation 
 
    III 26-well 10–
20% Tris-HCl 
Criterion gels 
Tau-5 MmAb  
AT8 MmAb 
PS396 MmAb 
PS404 Poly 
PS422 Poly 
GSK3 MmAb  
P-GSK3β Poly  
T-216 Poly  
Cdk5 Poly  
P35/25 RmAb 
β-Actin 
82E1 MmAb 
 
NU-4 MmAb 
Total tau  
P-Ser199/202Thr205  
P-Ser396  
P-Ser404 
P-Ser422 
GSK3α and GSK3β 
P-GSK3β Ser9  
P-GSK3α PY279/βPY216 
Total Cdk5  
Total p35 and p25  
Total β –actin 
Aβ1–16 (N-terminal end 
specific)  
Aβ oligomers 12- to 24-
mers (not monomers) 
1:1000 
1:1000 
1:1000 
1:1000 
1:1000 
1:500 
1:1000 
1:1000 
1:1000 
1:1000 
1:2000 
1:1000 
 
1:1000 
 
BioSource 
Pierce Invitrogen 
Invitrogen 
Invitrogen 
Invitrogen 
Sigma Aldrich 
Cell Signalling 
BioSource 
Cell Signalling 
Cell Signalling 
Abcam  
IBL 
 
Gift from Drs. 
Klein and Lacor  
IV 12-wells 15% 
Tris-HCl gels 
Histone H3 Poly 
Acetyl H3 Poly 
Phospho H3 Poly 
2MeH3 Poly 
 
Total H3 
Acetyl-lys14 H3  
P-Ser10 H3  
Dimethyl-lys 9 H3 
 
1:1000 
1:1000 
1:1000 
1:1000 
Millipore  
Millipore  
Millipore  
Millipore 
P = Phosphorylated; Poly = rabbit polyclonal antibody; MmAb = mouse monoclonal antibody; RmAb = 
rabbit monoclonal antibody 
 
 
Receptor autoradiography 
[125I]α-bungarotoxin autoradiography (Papers I, II) 
All the experimental procedure was performed in RT. Briefly, (1) frozen brain sections 
(10 µm) were thawed (2) pre-incubation with binding buffer (50 mM Tris-HCl, 1 mg 
BSA/ml, pH 7.4) (3) incubated in the same buffer containing 2 nM (Paper I), 1.55 nM 
(characterization: Paper II), 1.94 nM (treatment: Paper II) [125I]α-bungarotoxin (4) 
washed with 50 mM Tris-HCl buffer (5) rinsed in distilled water (6) dried (7) placed 
together with [125I]microstandards on [3H]-Hyperfilm and incubated for 8–29 days. 
 
[3H]MK-801 autoradiography (Paper I) 
All the experimental procedure was performed in RT. Briefly, (1) frozen brain sections 
(10 µm) were thawed (2) pre-incubated with binding buffer (3) incubated with the same 
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buffer, containing 10 nM [3H]MK-801 with 100 mM glutamic acid and 100 mM gly-
cine (4) washed with binding buffer (6) rinsed  in distilled water (7) dried, and (8) 
placed together with [3H]microstandards on 3H-Hyperfilm for 8 weeks. 
 
Post-processing and image analysis 
Receptor autoradiography films were developed in D-19 developer followed by fixing 
with Kodak fixer solution by manually.  
The autoradiograms were either analyzed with a video camera (CCD-72: Dage-
MTI, Michigan City, IN, USA) coupled to a Macintosh computer public domain NIH 
Image software (written by Wayne Rasband at the NIH, US) (Papers I), or first scanned 
by using a high-resolution scanner and then analyzed by using with Image J (Paper II). 
Optical density values were converted into fmol/mg tissue based on the standard 
curve derived from the [3H]microstandards, the [125I]microstandards or the standards 
composed of different concentrations of [125I]α-bungarotoxin. Specific binding was cal-
culated by subtracting non-specific binding from total binding. 
 
Immunohistochemical staining (Papers II and IV) 
Immunofluorescence labeling of Aβ and GFAP (Paper II) 
All procedures were performed at 25° C (unless otherwise indicated).  Immunofluores-
cence labeling of Aβ and GFAP was performed by (1) pre-treating frozen brain sections 
with concentrated formic acid (for Aβ) for 5 min (2) 1 h incubation with 5% normal 
goat serum (3) incubated with the primary antibody (1:100: 6E10, MAB 1560, Chemi-
con, Temecula, CA, USA) for Aβ deposits, or polyclonal rabbit anti-GFAP (1:300: 
Z0334, DakoCytomation, Glostrup, Denmark) to label astrocytes (4) incubated with 
Cy2-conjugated goat anti-mouse or Cy3-conjugated goat anti-rabbit secondary antibo-
dies (1:200 each: Chemicon, Temecula, CA, USA) (5) double immunofluorescence 
labeling of Aβ and GFAP was performed by incubating the sections with a cocktail of 
the primary antibodies followed by a cocktail of the secondary antibodies as indicated 
for the single fluorescence staining. For control staining, the primary serum was omit-
ted and this resulted in no detectable labeling. 
 
Immunofluorescence labeling of Acetylated histone H3and NeuN (Paper IV) 
Whole brains of mice were collected and were processed for paraffin embedding. To 
localize acetylated histones to neurons, sections were processed as follows in PBS-
based solutions and rinses: (1) (permeabilization) 0.1% Triton-X-100, 10 min, (2) 
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(blocking) 5% normal goat serum, 30 min, (3) anti-AcH3 and –NeuN (both 1:200), 48 
hr, (4) biotinylated anti-mouse IgG1 (1:250), 30 min, (5) avidin-biotin complex (1:50, 
Universal ABC kit, Vector Laboratories), 30 min, (6) streptavidin-AlexaFluor488 
(1:200) and anti-rabbit AlexaFluor594 (1:400), 1 hr. Slides were coverslipped and nuc-
lei counterstained with DAPI inclusion in mounting media (Vector Laboratories).  
 
Image analysis 
Images were generated by using an Anxiophot microscope (Carl Zeiss AG, Göttingen, 
Germany) equipped with a digital camera and a computerized imaging system. In Paper 
IV, images of AcH3 (red), NeuN (green), and DAPI (blue) staining were taken. ImageJ 
software was used and the ColocalizeRGB plugin (written by S. Caballero, 
http://grove.ufl.edu/~ksamn2/plugins.html#COLOC) to colocalize pixels in the three 
separate channels: red, green, and blue. The ratio of red-green (AcH3+NeuN) and red-
blue (AcH3+DAPT) was compared in neocortical tissue of APPswe and non-transgenic 
mice to indicate dual labeling of cells by anti-AcH3 and –NeuN; other channel ratios 
were used to validate staining specificity. Values are presented as the mean % co-
localization = (red-green)/(red-blue) obtained from 5 sections (3 images/section) for 
APPswe or non-transgenic mice. 
 
Statistical analysis 
Statistical analyses in all cases involved, the non-parametric Kruskal–Wallis test fol-
lowed by the Mann–Whitney post hoc test to assess the significance of differences be-
tween groups. In Paper II, III and Paper V one-way ANOVA followed by the Bonfer-
roni/Dunnett’s  post-hoc test was performed to calculate the significance of differences 
between hAChE-Tg//APPswe mice and FVB/N//C57B6 controls, APPswe mice and 
non-transgenic controls, as well as the significance of differences between hAChE-
Tg//APPswe mice and APPswe mice in the GFAP ELISA experiment. The same tests 
were also used to calculate the significance of differences between saline treatment and 
L(-)- or D(+)-nicotine treatment as regards autoradiographic and Aβ data. In addition, 
simple regression analysis was used to detect relationships between different parame-
ters (Paper I, III). One or two-way ANOVA followed by Dunnett’s post-hoc and Stu-
dent’s t-test were used for analyzing immunoblotting of histone modification in  
SH-SY5Y cells and Student’s t-test was used for the analysis data from brain tissue 
(APPswe mice or human) (Paper IV). One-way ANOVA followed by Bonferroni Post-
hoc test were used in the drug treated and control SH-SY5Y/APPswe cells (Paper V). 
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RESULTS AND DISCUSSIONS 
 
AGE-RELATED Aβ PATTERN IN APPswe AND hAChE-Tg//APPswe 
TRANSGENIC MOUSE MODELS 
It is well known that the pathological changes seen in AD patients are ongoing for 
decades before symptoms become manifest. To follow the human pathology from 
very early lifetime to the onset of AD is quite unrealistic. In this regard, the develop-
ment of transgenic mice provides a good tool to study the time course of biochemical 
and pathological processes from very early ages, which is inaccessible in humans. 
Most widely used mouse models express mutations in human APP,  providing aggra-
vated brain Aβ production. Along with mutations in APP, some models also express 
mutations in other AD-related proteins such as AChE, giving the opportunity to study 
even earlier Aβ pathology. 
 
PRESENCE OF Aβ-PEPTIDES STUDIED FROM 7 DAYS TO 15-MONTHS 
OF APPswe MICE 
The proportion of different forms of Aβ varied with different ages of APPswe transgen-
ic mice. Interestingly detection of both  soluble (Tris extracted) and  
 
 
 
Figure 3. Levels of soluble Aβ isoforms in the cortices of APPswe mice at 7, 21, 90-days, and 15- 
months old age. Mass spectrometric signals for the detected Aβ isoforms are quantified in these 
groups of APPswe mice. a P ≤0.05 and a aP ≤ 0.01 compared with APPswe mice at 7-days of age; b P ≤ 
0.05 compared with APPswe mice at 21-days of age ; c P ≤ 0.05 compared with APPswe mice at 90-
days of age. Values are expressed as mean ±SEM. 
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insoluble (Guanidinium-extracted) Aβ isoforms at 7 days of APPswe mice, indicating 
that these mice produce Aβ very early life (Paper I Table 1). APPswe mice younger 
than 15-months exhibited predominance of shorter peptides (Fig. 3). An age depen-
dent increase of total levels of Aβ1–42 was observed reflecting the plaques formation at 
older ages.  
 
AGE-RELATED Aβ OLIGOMERS IN APPswe MICE 
Studies have shown that the purified oligomers, but not the monomers play a critical 
role in the pathophysiology of AD79 . In Paper III, oligomers were quantified starting 
from pentamers up to 26-mers as early as from 7-days-old APPswe mice where pre-
vious studies could detect dodecamer at 6 month-old APPswe mice80,280. This finding 
suggests that the dodecamer is present in this mouse model earlier than previously 
reported. The highest levels of Aβ oligomers were present at 90-days of age, which 
might reflect an age-dependent aggregation of Aβ into larger assemblies (Fig. 4). Fur-
thermore, an interesting observation was that the levels of oligomers below 26-mers 
were lower in 15-month-old mice compared to 90-day-old mice, probably due to the 
increased fibrillization and aggregation in the older mice (Fig. 4). 
 
 
 
Figure 4: Levels of different oligomers (NU-4 antibody) in the cortices of 7, 21, 90-day,  and 15-
months-old APPswe mice. a P ≤0.05 and aaP ≤ 0.01 compared  with APPswe mice at 7-days of age; b P 
≤ 0.05 and bb P ≤ 0.01 compared with APPswe mice at 21-days of age ; c P ≤ 0.05 and ccP ≤ 0.05 com-
pared with APPswe mice at 90-days of age. Values are expressed as mean ±SEM.  
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AGE RELATED EFFECT OF Aβ ON SYNAPTOPHYSIN IN APPswe MICE 
Synapse loss is known as the best pathological correlate of cognitive impairment in AD 
90,281. Synaptophysin is a synaptic marker and its reduction indicates the loss of syn-
apse. Both fibrillar and soluble Aβ oligomers cause synaptic loss282,283. Conversely, 
high APP and/or Aβ result increased synaptophysin levels 284-286. On the contrary, syn-
aptic activity has been shown to increase Aβ secretion in vitro and in vivo189,287. 
 
 
Figure 5. Levels of synaptophysin in the cortices of 7, 21 and 90-day old APPswe mice. * P < 0.05 
and ** P < 0.01 compared with age-matched non-transgenic mice. a P < 0.05 and aa P < 0.01 compared 
with APPswe mice at 7-days of age. b P < 0.05 and bb P < 0.01 compared with APPswe mice at 21-days of 
age. Values are expressed as mean ± SEM. 
 
In paper I, 7-day-old APPswe mice exhibited significantly higher levels 
of synaptophysin compared with non-transgenic controls (Fig. 5). A significant reduc-
tion in cortical synaptophysin levels were observed at 21 and 90- days compared with 
7-days-old APPswe mice while there was an age dependent increase of synaptophysin 
levels in non-transgenic mice (Fig. 5). The findings of high levels of oligomers (Fig 4) 
and reduction of synaptophysin levels at 90-days of APPswe mice indicate that the oli-
gomers are causing the reduction of synaptic function. As discussed earlier, the ele-
vated synaptophysin levels could either be a compensatory response to early high Aβ 
levels, or be a result of neurotropic effects of APP or Aβ. sAPPα is known to plays an 
important role in neurotrophic/neuroprotective functions and synaptogenesis288,289. The 
highest levels of total sAPP and human sAPPα were found at 90 days, and as expected 
not at 7 days of age, in the APPswe mice (Paper I, Figs. 1 and 2, respectively), there-
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by supporting the hypothesis that soluble Aβ1–40 contributed to the increased synapto-
physin levels at 7-days of age.  
 
EARLIER Aβ PLAQUE PATHOLOGY IN hACHE-TG//APPswe MICE  
Most of the cortical AChE-S in AD brain was found associated with neuritic 
plaques290, in which it co-localized with both diffuse and senile plaques291,292. When  
 
 
 
 
Figure 6. Aβ in the cortex of hAChE-Tg//APPswe and APPswe mice. I) Levels of Aβ in the cortices 
of 1, 3 and 10- month of hAChE-Tg//APPswe and APPswe mice. A) Insoluble Aβ1–40  B) Soluble Aβ1–40  
C) Insoluble Aβ1–42. *P ≤ 0.05; ** P ≤ 0.01; and *** P ≤ 0.001, compared with age-matched APPswe 
mice. Data are expressed as mean±SEM (pmol/g tissue). II) Aβ plaques in (A) cortex and (D) hippocam-
pus of  7-month-old hAChE-Tg//APPswe mice. Plaques in the (B) cortex and hippocampus (E) of 10-
month-old hAChE-Tg//APPswe mice. Plaques in the cortex (C) and hippocampus (F) of 10-month-old 
APPswe mice. Scale bar 30μm. 
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APPswe mice were crossed with the mice over-expressing human AChE-S (hAChE-Tg 
mice) (Paper II), the double transgenic hAChE-Tg//APPswe mice exhibited signifi-
cantly increased levels of both insoluble Aβ1–40 and Aβ1–42 at 1 and 3-months of age 
while the levels of soluble Aβ1–40 were decreased at 1, 3, and 10 months of age, com-
pared with single transgenic APPswe mice (Fig. 6I). In addition, Aβ deposition in the 
cortex and hippocampus of double transgenic hAChE-Tg//APPswe mice was evident 
already at 7- months of age (Fig. 6II), which is earlier than the onset of plaque patholo-
gy in APPswe mice, that starts at 9-months of age293.  This finding is consistent with 
earlier studies that AChE-S may accelerate plaque formation230. Furthermore, the Aβ 
plaques appeared larger in 10-month-old hAChE-Tg//APPswe mice compared with the 
plaques in age-matched APPswe mice (Fig. 6II), which also support this interpretation. 
 
EFFECT OF Aβ ON α7 nAChRs AND NMDA RECEPTORS 
Aβ aggregation and loss of nAChRs as well as NMDA receptors are well-known fea 
 
 
Figure 7. Correlation of Aβ1-40 and [125I]α-bungarotoxin or [3H]MK-801 binding sites in the cortic-
es of APPswe mice. Soluble Aβ1-40 versus [125I]α-bungarotoxin (A) and [3H]MK-801(C); insoluble Aβ1-
40 versus [125I]α-bungarotoxin (B) and [3H]MK-801(D). Each point represents data from one mouse. 
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tures of AD brain, and it is believed that these features are linked to each other. Studies 
suggested that α7 nAChRs play a pivotal role in Aβ pathology166 while other studies 
showed that Aβ can reduce NMDA receptors 185. Moreover, it has been reported that 
Aβ mediates and promotes NMDA receptor endocytosis possibly via the α7 nAChR 
193. Therefore, we investigated [125I]α-bungarotoxin binding sites for α7 nAChR and 
[3H]MK-801 for NMDA receptors at different ages of APPswe mice (Paper I). We 
found a significant negative correlation between Aβ and α7 nAChR as well as Aβ and 
NMDA receptors, suggesting that high levels of Aβ decrease the number of α7 nAChR 
as well as NMDA receptor binding sites (Fig. 7). 
 
EFFECT OF β-AMYLOID ON TAU PHOSPHORYLATION AT DIFFERENT 
AGES OF APPswe MICE 
Hyperphosphorylation of tau is one of the key features of AD. The interaction of Aβ 
and tau phosphorylation remains controversial. However different Aβ species have 
been shown to induce tau hyperphosphorylation106,133-136. Recent studies suggest that 
the functional impacts of tau phosphorylation depend on the specific phosphorylation 
sites and the extent of phosphorylation118,294. In Paper III, we used the APPswe 
transgenic mice of different ages ranging from 7-days to 15- months (Table 2) to 
study whether increased Aβ causes tau phosphorylation of six epitopes (Paper III, 
Table 1). Surprisingly, we did not observed an increased phosphorylation at any of 
the age groups compared with the non-transgenic control (Paper III, Figs. 3 a–d). 
Instead, we found a reduction of overall tau phosphorylation in adult brain. The rea-
son for this finding could be due to differences between mouse and human tau or in-
dicate that Aβ alone is not sufficient to induce phosphorylation of tau.  
On the other hand, we observed that the smaller oligomers all showed a 
significant positive correlation with tau phosphorylation at AT8 and Ser396 (Fig. 8). 
There might be different plausible explanations for the temporal correlation of these 
isoforms on tau phosphorylation such as: (i) they might indicate a first sign of AD 
pathology; (iii) certain pathological features in the human brain might be missing in 
the mouse brain, and therefore the pathology cannot proceed and develop into hyper-
phosphorylation of tau; and (iv) there could be a developmental effect in the brain of 
these mice not normally found.  
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Figure 8. Correlation between small soluble Aβ oligomers and Tau phosphorylation in the cor-
tices of APPswe mice at 7, 21, 90-days and 15-months of age. (A) AT8 and  (B) Phospho-tau Ser 
396 Simple regression analysis was used. Values are expressed as mean. Each point represents data 
from one mouse. 
 
 
EFFECT OF β-AMYLOID ON DIFFERENT SIGNALING PATHWAYS 
The signal transduction is important to relay the external signals to the cell interior. 
When a signaling pathway is activated, it leads to a cascade of cellular responses. The 
extra cellular regulated protein kinase/mitogen-activated protein kinase ERK/MAPK 
pathway plays an important role in differentiation and early embryonic differentiation 
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295, synaptic plasticity296, cell survival 297  as well as neuroprotection 298. Therefore, we 
investigated ERK/MAPK signaling in APPswe mice due to the involvement in neuro-
protection (Paper I). Opposite to what we expected, a significant decrease in 
ERK2/MAPK activity was observed at 7-days of age, which may indicate that the ef-
fects of Aβ in the brain are not mediated via ERK/MAPK pathway (Paper I, Fig. 4). In 
addition, a significant increase in activity was observed in 21 and 90-day-old APPswe 
mice, suggesting chronic activation of this signal transduction cascade as a conse-
quence of the increased Aβ burden (Paper I, Fig. 4), which is in agreement with a pre-
vious study where chronic activation of ERK/MAPK signal transduction cascade was a 
consequence of the increased Aβ burden299.  
GSK3β 300, CDK5301 are the major kinases that mediate tau hyperphos-
phorylation. Studies also suggest complex links between Aβ, tau phosphorylation as 
well as with GSK3β and CDK5302,303. In Paper III, we investigated GSK3β and 
CDK5 in relation to phosphorylation of tau in APPswe mice of different ages (Table 
2). A significantly increased levels of phosphorylated GSK3β (P-Ser9 and Y216) was 
observed in 7-day-old APPswe mice compared with non-transgenic controls (Paper 
III, Fig. 4). There were no differences at any other time points, indicating that Aβ 
does not activate GSK3β to a greater extent in this mouse model. 
Hyperactivation of CDK5 due to the conversion of p35 to p25 by the 
calcium dependent protease calpain during neurotoxicity also contributes to the pa-
thological state of neurons. Therefore, we investigated CDK5, p35 as well as p25 
(Paper III). We found significantly reduced levels of CDK5 in 7-days-old APPswe 
(Paper III Fig. 5a) and also decreased levels of p35 in 90-days-old APPswe mice 
compared to age-matched non-transgenic controls (Paper III Fig. 5c) while there was 
a reduction in p25 levels in 7-days-old APPswe mice compared to non-transgenic 
controls, followed by an increase at 15-months of age (Paper III Fig. 5b) This result 
of high levels of p25 at older ages might be due to the prolonged Aβ exposure of the 
cells, which is in agreement with the studies where the conversion of p35 to p25 oc-
curs in the presence of various neuronal insults, such as excitotoxic glutamate, hydro-
gen superoxide H2O2 and Aβ peptides 304.  
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EFFECT OF Aβ ON HISTONE MODIFICATION 
The regulation of gene expression in response to environmental factors may play an 
important role in the progression of AD pathology. Without changes to the DNA se-
quence, gene expression can be modulated by epigenetic mechanisms such as histone 
modifications305. It is known that histone modification by methylation and phosphory-
lation are increased in AD brain226,227. In Paper IV we investigated changes in the his-
tone levels associated with soluble Aβ exposure in vitro in SH-SY5Y/APPswe cells 
and primary cortico-hippocampal neuronal cultures, and in vivo in APPswe and human 
cerebral cortex.    
 
 
 
Figure 9. Modification of histone H3 in  (A) 4-months-old APPswe at (I) Acetylate lysine 14 
(ACH3) (II) Di-methylate lysine 9 H3, and (III) Total histone H3; and (B) AD brain.  
Values are expressed as mean ± SEM. 
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In APPswe mice, elevated levels of AcH3 and 2MeH3 were observed  in the 
different brain regions compared to non-transgenic controls (Fig. 9A I and II) despite 
reduced TH3 (Fig. 9A III). Consistent with these findings, AcH3 and 2MeH3 were 
significantly increased in the neocortical (occipital cortex) histone extracts in AD com-
pared to non-demented, age-matched control subjects (Fig. 9B). As a conformation, 
DAPT treatment in SH-SY5Y/APPswe cells, a γ-secretase inhibitor showed a reduction 
of both Aβ1-40 and AcH3. Besides, AcH3 (Paper IV Fig 3C) but not 2MeH3 (Paper IV 
Fig. 3D) were significantly increased with sodium-butyrate a histone de-acetylase inhi-
bitor. These results suggest that acute and sustained Aβ exposure induced disrupted 
neocortical histone H3 homeostasis in cultures and APPswe brain, but may be sustained 
with chronic Aβ exposure as observed in end-stage AD neocortex. 
 
EFFECTS OF CHOLINERGIC DRUG TREATMENT IN TRANSGENIC 
MOUSE MODEL AND SH-SY5Y/APPswe CELLS 
Numerous studies suggested that cholinergic drugs might interact with the ongoing 
neuropathological processes beside their usual cholinergic effect. Disease modifying 
agent would be the therapy of choice for AD treatment. Inhibition of Aβ peptides or 
modulation of amyloid processing would be one of the major disease modifying targets 
for AD.  
 
Effect of nicotine treatment in hAChE-Tg//APPswe mice  
Studies have shown that both L(-) and D(+)-enantiomers of nicotine affect early stages 
of Aβ aggregation including delaying oligomerization and fibril formation, and thus 
reducing Aβ toxicity306. In addition, Aβ reduction was observed by chronic nicotine 
[L(-)-nicotine] treatment in 9-month-old APPswe mice (time of appearance of  Aβ pla-
que)155,307. Opposite to these studies, in Paper II hAChE-Tg//APPswe mice of 14-
months of age, treated with both L(-) and  D(+)-nicotine for 10 days showed increased 
soluble Aβ1–42 (Fig. 10Ai) and insoluble Aβ1–40 (Fig. 10Aii) might be due to the over-
expression of AChE in combination with Aβ pathology.   
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Figure 10. Levels of Aβ in (A) cortices of hAChE-Tg//APPswe mice treated nicotine: (i) Le-
vels of soluble Aβ1-40 (ii) Levels of soluble Aβ1-42. (B) Release of soluble Aβ1-40  and Aβ1-42  
from SH-SY5Y/APPswe cells treated with (i) Nicotine, (ii) JN403, and (iii) Varenicline. 
*P≤0.05; **P≤0.01  and ***P≤0.001, compared with untreated group. Values are expressed 
as mean ± SEM.  
 
 
 
Effect of nicotinic agonists in SH-SY5Y/APPswe cells  
A functional interaction of α7 nAChR–Aβ  has been first described over a decade 
ago166; since then many studies have reported seemingly consequences of this function 
emphasizing a complex biology that underlies this interaction. Studies showed that α7 
nAChR agonists provided neuroprotection against toxic effect of Aβ308. Therefore, it 
would be interesting to study α7 nAChR agonists on Aβ. 
In Paper V, SH-SY5Y/APPswe cells were treated with nicotine as well 
as varenicline (a partial α7 nAChRs agonist) and JN403 (a pure α7 nAChRs agonist) 
for 72 hours. The release of Aβ1-40 was significantly reduced by nicotine (Fig. 10Bi) 
and varenicline (Fig. 10Biii) while Aβ1-42 were significantly increased by the treatment 
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with nicotine (Fig. 10Bi) and JN403 (Fig. 10Bii) compared to the control. The reduc-
tion of Aβ1-40 release by nicotine and varenicline would be due to reducing the total 
Aβ1-40 production or increase degradation while the result of increased release of Aβ1-42 
might be due to increase production or increase clearance of Aβ from the intracellular 
pool. However, complete mechanisms need to be understood to see the treatment effect 
in the intracellular aspect. 
 
Effect of nicotine on APP 
To investigate whether the selected nicotinic agonists could affect the amyloid 
processing in SH-SY5Y/APPswe cells, the amount of the release of sAPPα (non-
amyloidogenic pathway) and sAPPβ (amyloidogenic pathway) were assessed. Varenic-
line reduced release of both sAPPα and sAPPβ compared to the untreated cells (Paper 
V, Figs. 3C and 4C). On the other hand, JN403 only reduced the sAPPβ levels (Paper 
V Fig 4B) while nicotine did not change either the sAPPα or sAPPβ (Paper V, Figs. 
3A and 4A). Therefore, the results might indicate that different nicotinic agonists might 
have different mechanism of action.  
 
Effect of nicotine on α7 nAChRs and astrocytes  
It is well known that nicotinic agonists including nicotine , up-regulate the nAChRs, 
mainly the α4 nAChRs, while the α7 nAChRs are more resistant155,293. It has been sug-
gested that there might be a functional interaction between α7 nAChR and Aβ 166. 
Consistent with this hypothesis, we found an increased levels of α7 nAChR in the cor-
tices and hippocampi of  hAChE-Tg//APPswe transgenic mice treated with nicotine 
(Paper II, Table 1)- indicating a link to the elevated levels of Aβ in these mice. Fur-
thermore, nicotine reduced the levels of GFAP- a marker for activated astrocytes in 
hAChE-Tg//APPswe mice, demonstrating the anti-inflammatory effect (Fig. 11). This 
is in agreement with the recent study where nicotine has been shown to reduce neuroin-
flammation 309 . 
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Figure 11. Expression of GFAP (in ELISA) in the hippocampus of hAChETg//APPswe and 
FVB/N//C57B6 control mice treated with saline, D(+)-nicotine, or L(-)-nicotine * P≤0.05; and ** 
P≤0.01, compared with control mice in the same treatment group. # P≤0.05, compared with saline-
treated hAChE-Tg//APPswe mice or controls, respectively. Results are expressed as mean GFAP im-
munoreactivity/mg protein ±S.E.M. 
 
Effect of ChEIs on amyloid processing  
A number of studies have shown that ChEI treatment seems to be beneficial by hav-
ing a neurotrophic effect310, which also includes inducing neurogenesis in adult ro-
dents273,311 as well as long-term stabilization of neuronal functional activity in those 
brain regions where cognitive impairment is obvious in AD246,312-314. 
In Paper V, we treated SH-SY5Y/APPswe cells with galantamine as 
well as with both enantiomers (+) and (-)-phenserine. We observed that (-)-phenserine 
increased the release of Aβ1-42 (Paper V Fig. 2E), but did not have any effect on sAPP. 
Whereas, (+)-phenserine, which is a weak ChE inhibitor and the anti-amyloid drug 
reduced Aβ1-40 (Paper V Fig. 1F), as well as sAPPβ (Paper V Fig. 4F) indicating 
that the reduction of Aβ1-40 was due to reduced levels of sAPPβ. These different find-
ings of the two enantiomers of phenserine might have some other dissimilar proper-
ties, which include different regulatory mechanisms on amyloid processing. On the 
other hand, galantamine did not alter the release of Aβ levels while it reduced both 
sAPPα (Paper V Fig. 3D), and sAPPβ (Paper V Fig. 4D), indicating that galantamine 
interacts with APP processing.  
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CONCLUDING REMARKS 
This work has been investigated the dynamic changes of different Aβ isoforms in rela-
tion to age in two types of AD-related transgenic mouse models and explored how 
these Aβ isoforms influence the synapses, cholinergic and glutamatergic receptors, 
phosphorylation of tau, inflammatory processes and how different cholinergic drugs 
affect Aβ and its processing.  Figure 12 contains a suggestion of the time course of Aβ 
and its influence on synapse in the AD-related transgenic mouse model.  
 
 
Figure 12: Illustration of the time course of different processes in APPswe transgenic mouse studied in 
this thesis.   
 
From the main findings in this thesis the following conclusions can be drawn: 
 
• The onset and consequences of Aβ pathology is exihited early in the brain of 
the different transgenic mouse models. The level of soluble Aβ1–40 was the 
most abundant isoform in the cortices of APPswe mice. The levels remained 
fairly unchanged up to 15 months of age. There was an age-dependent shift in 
the Aβ pattern, where the brains of younger APPswe mice contained more of 
the shorter Aβ1–16 and Aβ1–17 peptide while the longer Aβ1–42 (which is more 
prone to aggregate) increased with age.  
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• Oligomeric Aβ levels were highest at 90 days of age in the APPswe transgenic 
mouse model, making it a very interesting time point to study changes in other 
neuropathological hallmarks. The reduced levels of synaptophysin at that time 
point indicate that Aβ oligomers influence the number of synapses and 
thereby causing functional deficits in the brain. 
 
• The findings of elevated acytylation and di-methylation of histone H3 in 
transgenic mice (as well as in postmortem AD brain) at the same age indicates 
that oligomeric Aβ causes changes in gene transcription in the cells of the 
brain. This might in turn lead to functional consequences and reduced 
cognitive performance.  
 
• The different human Aβ isoforms did not directly increase tau 
phosphorylation in the APPswe mice. The reason for this finding could be due 
to the diffences in human and mouse tau or indicate that Aβ alone is not 
sufficient to induce phosphorylation of tau in this mouse model. 
 
• Age-matched hAChE-Tg//APPswe mice displayed a different pattern of solu-
ble and insoluble Aβ compared to the APPswe mice. This is probably due to 
the overexpression of AChE, leading to increased aggregation of Aβ and con-
sequently earlier plaque formation. These also suggest that early intervention 
is needed to effectively reduce Aβ burden. 
 
• The cholinergic drugs tested in this study all had effect on Aβ processing in 
SH-SH5Y/APPswe cells. Nicotine, the α7 nAChR agonist JN403 as well as  
(-)-phenserine showed increased release of Aβ probably due to a concurrent 
decrease of the intracellular Aβ pool. Moreover, reduction of sAPPβ by the 
anti-amyloid drug (+)-phenserine, the ChEI galantamine and JN403 as well as 
reduction of both sAPPα and sAPPβ by the nAChR agonist varenicline 
indicating that these substances modify the processing of amyloid.  
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In conclusion, to develop new therapeutic strategies it is important to 
understand the disease mechanisms. Therefore, this thesis has hopefully contributed 
valuble information in understanding the mechanisms of age-related Aβ pathology as 
well as provided suggestions of therapeutic targets.  
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